BOSTON , Oct. 9, 2024 /PRNewswire/ -- HotSpot Therapeutics, Inc., a biotechnology company pioneering the discovery and development of oral, small molecule allosteric therapies targeting regulatory sites on proteins referred to as "natural hotspots," today announced it will present preclinical data from the Company's mucosa-associated lymphoid tissue lymphoma translocation protein 1 (MALT1) CARD11-BCL10-MALT1 (CBM) signalosome glue program highlighting its potential NF-kB-driven solid tumors in a poster presentation at the 36th EORTC-NCI-AACR Symposium, taking place October 23-25, 2024 , in Barcelona, Spain .
Presentation details are as follows: Title: Targeting the CBM signalosome with a MALT1 scaffolding inhibitor for treatment of NFkB driven solid tumors Poster Session: Molecular Targeted Agents Session Date and Time: Wed., Oct. 23, 2024 , 12:00-19:00 CEST Abstract Number: 105 About HotSpot Therapeutics, Inc.
HotSpot Therapeutics, Inc. is a clinical-stage biotechnology company that is pioneering a new class of allosteric drugs that target certain naturally occurring pockets on proteins called "natural hotspots." These pockets are decisive in controlling a protein's cellular function and have significant potential for new drug discovery by enabling the systematic design of potent and selective small molecules with novel pharmacology.
The Company's proprietary Smart Allostery TM platform combines computational approaches and AI-driven data mining of large and diverse data set.
